Diplopia

Seeing double: the low carb diet

A 38 year old white Scottish man with mild learning difficulties (able to read and write but not to maintain employment) presented with a three day history of diplopia and agitation, after seven days....

Unilateral Proptosis

A 40-year-old man presents with left periorbital swelling and pain,which developed gradually over 2 months with no history of trauma, fever, or recent sinusitis. He has no previous medical illness and...

UCB Announces New Data for VIMPAT® (lacosamide) at the 66th Annual Meeting of the American Epilepsy Society

ATLANTA, Nov. 29, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data...

Merz North America Congratulates Glenn Block on His Induction into the Canadian Healthcare Marketing Hall of Fame

Merz North America (affiliate of Merz Pharma Group) congratulates Glenn Block, President and General Manager of Merz Pharma Canada, Ltd., who has been selected for induction into...

UCB Announces New Data to Increase Understanding of Short- and Long-Term Clinical Profile of Antiepileptic Drug VIMPAT® (lacosamide)

ATLANTA, Dec. 4, 2012 /PRNewswire/ -- Data presented at the 66th Annual Meeting of the American Epilepsy Society Post hoc, population-based analysis of pivotal trials explored the efficacy of VIMPA...

Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for STEDESA® (eslicarbazepine acetate) as a Once-Daily Adjunctive Therapy for Partial-onset Seizures in Adults with Epilepsy

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) resubm...

VIMPAT® (lacosamide) generates positive results in U.S. Phase 3 monotherapy study

ATLANTA and BRUSSELS, March 5, 2013 /PRNewswire/ -- regulated information – UCB today announced positive results of a Phase 3 study designed to evaluate the efficacy and safety of conversio...

Merz North America (Merz Aesthetics, Inc. and Merz Pharmaceuticals, LLC) Announces the End of Court-Ordered Injunction

Merz North America (Merz Aesthetics, Inc. and Merz Pharmaceuticals, LLC) announces that effective today, January 9, 2013, the court-ordered injunction has been lifted and patients...

Acute-onset diplopia.

Purpose:  To investigate the clinical features of all patients with acute-onset diplopia presenting to the ophthalmology department. Methods:  The notes of every patient who presented with acute o...

Case 15-2012: Diplopia, headaches, and papilledema.

Diplopia and ptosis.

Oxcarbazepine Versus Carbamazepine in the Treatment of Paroxysmal Kinesigenic Dyskinesia.

ABSTRACT Paroxysmal kinesigenic dyskinesia (PKD) is an uncommon neurological disorder, consisting of brief attacks of involuntary movements triggered by sudden action. Patients with PKD generally resp...

Simultaneous papilledema and optic disc drusen in a child.

Idiopathic intracranial hypertension is a headache syndrome characterized by elevated intracranial pressure with normal cerebrospinal fluid content, normal cranial imaging, and elevated appearance of...